2076975 2077203
최종편집 2024-07-22 22:15 (월)
Sanofi launches cold agglutinin disease treatment Enjaymo in Korean market
상태바
Sanofi launches cold agglutinin disease treatment Enjaymo in Korean market
  • Hyeokgi Lee, Newsmp
  • 승인 2023.07.19 23:39
  • 댓글 0
이 기사를 공유합니다

New treatment opportunity expected to patients with cold agglutinin disease

[Newsmp] On the 12th, the Ministry of Food and Drug Safety granted approval to Sanofi's Enjaymo (ingredient: sutimlimab) for treating hemolysis in adult patients with cold agglutinin disease.

Enjaymo is indicated for hemolytic therapy in adult patients with autoimmune hemolytic anemia (AIHA), a type of cold agglutinin disease.

Cold agglutinin disease is a rare type of autoimmune hemolytic anemia that causes hemolysis by agglutinating red blood cells at temperatures below normal body temperature.

By binding to complement protein component 1, s subcomponent (C1s), Enjaymo, an immunoglobulin G subclass 4 (IgG4) monoclonal antibody, inhibits the classical complement pathway.


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.